Financial Review: Jaguar Health (NASDAQ:JAGX) and Rapport Therapeutics (NASDAQ:RAPP)

Jaguar Health (NASDAQ:JAGX) and Rapport Therapeutics (NASDAQ:RAPP) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Jaguar Health and Rapport Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jaguar Health	0	0	0	0	0.00
Rapport Therapeutics	0	0	3	0	3.00

Rapport Therapeutics has a consensus price target of $35.00, suggesting a potential upside of 31.14%. Given Rapport Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Rapport Therapeutics is more favorable than Jaguar Health.

Valuation and Earnings

This table compares Jaguar Health and Rapport Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jaguar Health	$9.76 million	0.89	-$41.30 million	N/A	N/A
Rapport Therapeutics	N/A	N/A	-$34.79 million	N/A	N/A

Rapport Therapeutics has lower revenue, but higher earnings than Jaguar Health.

Profitability

This table compares Jaguar Health and Rapport Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Jaguar Health	-350.18%	-412.63%	-67.24%
Rapport Therapeutics	N/A	N/A	N/A

Insider and Institutional Ownership

12.0% of Jaguar Health shares are owned by institutional investors. 0.0% of Jaguar Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Rapport Therapeutics beats Jaguar Health on 7 of the 10 factors compared between the two stocks.

About Jaguar Health

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.

About Rapport Therapeutics

Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.